December 1, 2023
Therapeutic use of oligonucleotides: Challenges and Opportunities
While cancer applications are still dominant for oligonucleotide-based drugs, CNS, diabetes and cardiovascular conditions are starting to represent a significant share. To investigate which structural elements novel drugs in this area may have in common could be an important next step to trigger and shape new technology trends. Learn more in this NegotiumBio case study
November 3, 2023
A look back at CPhI 2023: Is there too much ‘Me-Too’ in our industry?
On the occasion of our industry’s largest and most sought-after annual event, NegotiumBio’s Christoph Becker shares some personal reflections on how CDMOs can get the edge if it comes to gaining verified business leads, and how a deeper AI-driven IP exploration can help them to better position themselves both from a capacity expansion and technology investment perspective. Find out more
October 23, 2023
NegotiumBio and EconSight announced today that the companies have entered a strategic partnership to provide AI-driven tailor-made business and technology development solutions to their customers the pharma and life science sector. Combining NegotiumBio’s profound industry expertise with Econsight’s groundbreaking artificial intelligence solutions is expected to create significant value, as they together tap into new markets and capitalize on emerging opportunities. Read more
July 6, 2023
The NegotiumBio team was delighted to participate as Expert Opinion Partner at BOS Basel 2023, an event that brings together stakeholders in R&D outsourcing to share experience, build existing outsourcing partnerships and forge new buyer/supplier business relationships. Learn more
April 19, 2023
An Eleventh Hour Solution – Provided by NegotiumBio
The eleventh hour is defined as the last moment (or as almost, but not quite too late) to do something – which aptly describes the timing and process for the interaction NegotiumBio had with a client. Find out more in this case study.